Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocksAUROPHARMA
resources
AUROPHARMA

Aurobindo Pharma Ltd.

NSE: AUROPHARMA
BSE: 524804
Sector: Healthcare
Industry: Pharmaceuticals
1,608.00-13.3 (-0.82%)
24 Aug, 12:00 AM

Annual Reports and Financial Documents

Aurobindo Pharma Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

Corporate Announcements and Regulatory Filings

Aurobindo Pharma Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.
  1. General24 Aug 2026
    Completion Of US FDA Inspection At Lannett Company LLC, A Wholly Owned Subsidiary Of Aurobindo Pharma USA, Inc.
    Intimation of completion of US FDA inspection at Lannett Company LLC., a wholly owned subsidiary of Aurobindo Pharma, USA Inc.
  2. General21 Aug 2026
    Completion Of US FDA Inspection At Auro Peptides Ltd, A Subsidiary/Business Arm Of The Company.
    Intimation of completion of US FDA inspection at Auro Peptides Limited, a subsidiary of the Company.
  3. General17 Aug 2026
    Classification Of US FDA Inspection At Raleigh Plant, North Carolina, Owned By Aurolife Pharma LLC, A Wholly Owned Step-Down Subsidiary Of The Company, As Voluntary Action Indicated (VAI)
    Intimation of classification of US FDA inspection at Raleigh Plant, North Carolina, owned by Aurolife LLF, a wholly owned step down subsidiary of the Company, as Voluntary Actioin Indicated (VAI).
  4. Analyst / Investor Meet14 Aug 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Intimation of participation of officials of the Company in investors / analysts meet to be held on August 19, 2026
  5. General14 Aug 2026
    Unit I Of Eugia Pharma Specialities Ltd. Received A Warning Letter From US FDA
    Intimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
  6. Acquisition13 Aug 2026
    Announcement under Regulation 30 (LODR)-Acquisition
    Intimation of incorporation of a new wholly owned subsidiary.
  7. Newspaper Publication7 Aug 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    Submission of copies of notice published by the Company on August 7, 2026 in Business Standard and Nava Telangana regarding special window for re-lodgement of transfer requests of physical shares.
  8. Newspaper Publication7 Aug 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    Submission of copies of newspaper advertisements of the financial results of the Company for the first quarter ended June 30, 2026 as published in Business Standard and Nava Telangana on ....
  9. Analyst / Investor Meet6 Aug 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Intimation of participation by the officials of the Company in the Investor/Analyst Meet to be held on August 11 to 13, 2026 in Singapore & Hong Kong
  10. Restructuring5 Aug 2026
    Announcement under Regulation 30 (LODR)-Restructuring
    Intimation of proposal of merger of two wholly owned stepdown subsidiaries with a wholly owned subsidiary.
  11. Press Release / Media Release5 Aug 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Submission of Press Release on financial results of the Company for the first quarter ended June 30, 2026.
  12. Outcome of Board Meeting5 Aug 2026
    Board Meeting Outcome for Outcome Of The Board Meeting Held On August 5, 2026
    The Board of Directors of the Company at its meeting held today, August 5, 2026, has, inter alia, considered and approved: a) the standalone and consolidated Unaudited Financial Results ....
  13. Newspaper Publication4 Aug 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    Submission of copies of notice published in newspapers.
  14. General4 Aug 2026
    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
    Confirmation of dispatch of letter to the shareholders who have not registered their email ids, providing weblink for integrated Annual Report 2025-26.
  15. Business Responsibility and Sustainability Reporting (BRSR)3 Aug 2026
    Business Responsibility and Sustainability Reporting (BRSR)
    Submission of BRSR for FY 2025-26.
  16. AGM3 Aug 2026
    Notice Of 39Th Annual General Meeting
    Submission of Notice of 39th Annual General Meeting of the Company to be held August 27, 2026.
  17. Reg. 34 (1) Annual Report3 Aug 2026
    Reg. 34 (1) Annual Report.
    Submission of Integrated Annual Report 2025-26
  18. Newspaper Publication30 Jul 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    Submission of copies of notice published in newspapers intimating the shareholders that the 39th AGM of the Company will be held on August 27, 2026.
  19. AGM29 Jul 2026
    Intimation Of 39Th Annual General Meeting Of Aurobindo Pharma Limited.
    Intimation of 39th Annual General Meeting of Aurobindo Pharma Limited to be held on August 27, 2026.
  20. Analyst / Investor Meet29 Jul 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Intimation of schedule of Earnings Call to be held on August 6, 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the first quarter ended June 30, 2026.

Frequently Asked Questions

Where can I download the annual report of Aurobindo Pharma Ltd.?
Annual reports of Aurobindo Pharma Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.
Where can I find the quarterly results of Aurobindo Pharma Ltd.?
Quarterly earnings results and presentations of Aurobindo Pharma Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.
Does Aurobindo Pharma Ltd. publish earnings call transcripts?
Earnings call transcripts of Aurobindo Pharma Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.
Where can I find investor presentations of Aurobindo Pharma Ltd.?
Investor presentations and annual day presentations of Aurobindo Pharma Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.
What are the recent corporate announcements of Aurobindo Pharma Ltd.?
Corporate announcements and regulatory filings of Aurobindo Pharma Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.
How do I access the regulatory filings of Aurobindo Pharma Ltd.?
Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Aurobindo Pharma Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.
What is the ISIN of Aurobindo Pharma Ltd.?
The ISIN (International Securities Identification Number) of Aurobindo Pharma Ltd. is INE406A01037. This is the unique identifier used across exchanges and depositories.
On which stock exchange is Aurobindo Pharma Ltd. listed?
Aurobindo Pharma Ltd. is listed on NSE and BSE. The NSE symbol is AUROPHARMA and the BSE code is -.
Where can I find the shareholding pattern of Aurobindo Pharma Ltd.?
The quarterly shareholding pattern of Aurobindo Pharma Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.
How current is the data for Aurobindo Pharma Ltd. on Sharpely?
Share price data for Aurobindo Pharma Ltd. is updated as of 24 Aug 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.